Patent intelligence · CA
CA 2677623
FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES
FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES
Patent details — CA 2677623
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Aug 14, 2008
- Expiration
- Aug 9, 2028
- Applicant
- ALPHAPHARM PTY LTD [AU]
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 16 A I, A61K 9/ 52 A I, A61K/31135
Quick answer
CA 2677623 (FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES) is held by ALPHAPHARM PTY LTD [AU]. Status: granted. Granted Aug 14, 2008. Expires Aug 9, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALPHAPHARM PTY LTD [AU]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 16 A I, A61K 9/ 52 A I, A61K/31135, A61K/31551, A61K/92072
More from ALPHAPHARM PTY LTD [AU]
Related pharmaceutical patents in our USPTO index.
-
CA 2767560
ATOVAQUONE A DIAMETRE DE PARTICULES (D<SB>90</SB>) VARIANT DE PLUS DE 3UM A ENVIRON 10UM
granted -
CA 2765866
FORMULATION PHARMACEUTIQUE
granted -
CA 2712282
COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE
granted -
CA 2702664
FORMULATION PHARMACEUTIQUE A LIBERATION CONTROLEE
granted -
WO 2009026621
COMPOSÉ ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2673419
COMPOSITION PHARMACEUTIQUE
granted -
CA 2673418
COMPOSE ET COMPOSITION PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 2677623?
CA 2677623 (FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES) is held by ALPHAPHARM PTY LTD [AU]. Status: granted. Granted Aug 14, 2008. Expires Aug 9, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2677623?
ALPHAPHARM PTY LTD [AU] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does CA 2677623 expire?
Our index shows an expiration date of Aug 9, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.